GSK Consumer offer very good; Ranbaxy Lipitor recall to hurt
Ranjit Kapadia, senior VP, Centrum Broking, feels that the 30 per cent higher offer for GSK shareholders from its parent is very good and investors should tender their stock in the offer. He adds that Ranbaxy's Lipitor recall will hurt its market share if the issue gets delayed beyond the two weeks the management seems to be indicating at this stage.
